We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Explainable AI Tool Improves Brain Disorder Screening from 4D fMRI

By HospiMedica International staff writers
Posted on 26 Sep 2026

Functional magnetic resonance imaging (fMRI) captures changes in brain activity over time, but the resulting image sequences can be difficult to analyze. More...

Screening for brain disorders requires assessing both where activity occurs and how it changes over time. Clinicians also need insight into the evidence behind an artificial intelligence (AI) prediction, not just its diagnostic label. Researchers have now developed an AI approach designed to combine these spatial and temporal features while making screening more transparent and efficient.

At InfoLab, Sungkyunkwan University (SKKU; Seoul, South Korea), researchers developed the 4D fMRI CrossFormer (4DfCF), a vision transformer architecture for four-dimensional fMRI data. The model analyzes spatial and temporal patterns of brain activity together. It examines activity at different scales and learns relationships between both nearby and distant brain regions. 

The researchers also applied an explainable AI technique to the model’s predictions. It produces visual maps showing which brain regions contributed most strongly to each prediction. These maps give clinicians and researchers information to review alongside the model’s output, without replacing a physician’s judgment. 

The team evaluated 4DfCF using three benchmark fMRI datasets containing scans from people with attention-deficit/hyperactivity disorder, Alzheimer’s disease or autism spectrum disorder. The model outperformed the comparison models assessed across all three datasets. It achieved an F1 score of 96.28% on the Alzheimer’s disease dataset identified as ADNI. 

A model initially trained on one fMRI dataset also learned another dataset faster and achieved improved performance. The main 4DfCF model has approximately 10.34 million parameters, while the smaller 4DfCF-T version has about 4.18 million. Both require fewer computational resources than several larger comparison models. The research was published in the IEEE Journal of Biomedical and Health Informatics. 

The findings come from benchmark datasets rather than clinical deployment. Validation across hospitals and patient populations remains necessary. The results also suggest that pretrained models might eventually be adapted to other brain disorders and neuroimaging tasks.

Related Links
Sungkyunkwan University


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Fetal Monitor
BT-380
Patient Preoperative Skin Preparation
BD ChloraPrep
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image Credit: Adobe Stock

AI Platform Personalizes Support Between Visits for Cancer Survivors

Cancer survivors often manage persistent side effects after treatment, including fatigue, anxiety, uncertainty, symptoms, stress, and questions between appointments. Clinical teams need ways to maintain... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: The proposed acquisition would add NeoCast, an investigational next-generation liquid embolic technology for chronic subdural hematoma (cSDH), to Terumo Neuro’s neurovascular portfolio. (Photo courtesy of Arsenal Medical)

Terumo Neuro Acquisition Advances Liquid Embolic Technology for Chronic Subdural Hematoma

Terumo Neuro (Aliso Viejo, CA, USA) signed an agreement to acquire Arsenal Medical Inc. (Waltham, MA, USA), a privately held, clinical-stage biomaterials company. The proposed acquisition would add NeoCast,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.